Drug profile

The FDA adverse-event record for Unspecified Lyme Vaccine

39 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Lyme Vaccine. See the species affected, top reactions, and outcomes below.

39
adverse-event reports
2.6%
death-coded share
Dog
most-reported species
23
Lack of efficacy (bacteria) - Borrelia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
39
Total Reports
1
Deaths Reported
2.6%
Death Rate

Active Ingredients

Unspecified Lyme Vaccine

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 39

Most Affected Breeds

Shepherd Dog - German 7
Retriever - Labrador 5
Crossbred Canine/dog 3
Dog (unknown) 2
Chihuahua 2
Mountain Dog - Bernese 2
Saint Bernard Dog 1
Terrier - Yorkshire 1
Collie - Border 1
Siberian Husky 1

Most Reported Reactions

Lack of efficacy (bacteria) - Borrelia 23
Lack of efficacy (ectoparasite) - tick NOS 9
Lack of efficacy (bacteria) - Anaplasma 4
Not eating 3
Medication error NOS 3
Behavioural disorder NOS 3
Neck pain - neurological 2
Lethargy (see also Central nervous system depression in Neurological) 2
Intentional misuse 2
Vestibular disorder NOS 2
Polydipsia 2
Disorientation 2

Outcome Breakdown

Ongoing
27 (69.2%)
Outcome Unknown
7 (17.9%)
Recovered/Normal
4 (10.3%)
Died
1 (2.6%)

Unspecified Lyme Vaccine Adverse Event Insights

39 reports name Unspecified Lyme Vaccine; 1 recorded a death outcome (2.6% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Lyme Vaccine. Administration routes: Unknown, Subcutaneous.

By species: Dog (39 reports). By breed: Shepherd Dog - German (7), Retriever - Labrador (5), Crossbred Canine/dog (3).

Leading clinical signs: Lack of efficacy (bacteria) - Borrelia (23), Lack of efficacy (ectoparasite) - tick NOS (9), Lack of efficacy (bacteria) - Anaplasma (4), Not eating (3). Outcome, 39 coded reports: Ongoing leads at 69.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.